Trellis Bioscience raises $9 million in Series C funding to advance clinical development of Calpurbatug (TRL1068), targeting antibiotic-resistant infections. New and existing investors including AMR Action Fund and New Science Ventures participated.
Amount Raised
$9 Million
Round Type
Series C
Investors
Description
Trellis Bioscience announced the closing of a $9 million Series C financing aimed at supporting the Phase 2 trial of Calpurbatug (TRL1068) for chronic prosthetic joint infections. The funding attracted participation from both existing and new investors. This investment solidifies Trellis's total equity funding at approximately $35 million, complemented by substantial non-dilutive grant support.
Who to call at Trellis Bioscience, and when
A new round usually means Trellis Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Trellis Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Trellis Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Trellis Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Trellis Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Trellis Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.